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Four  studies  were  conducted  to evaluate  the  speed  of  kill,  effect  on  egg  production,  and  efﬁcacy  in  a
simulated  infested-home  environment  of a novel  isoxazoline,  sarolaner  (SimparicaTM, Zoetis),  against
ﬂeas  on  dogs.  Individually  identiﬁed  and housed,  purpose-bred  Beagles  were  used  in  each  study  and
were  allocated  randomly  to groups  based  on  pretreatment  parasite  counts.  In  two  speed  of  kill studies,
groups  of dogs  infested  with  100  ﬂeas  prior  to  treatment  were  treated  orally  with  placebo  or sarolaner
tablets  providing  the  minimum  dose  of  2  mg/kg  and  then  re-infested  with  ﬂeas  weekly  for ﬁve weeks  post-
treatment.  Comb  counts  were  conducted  to  determine  the  numbers  of  viable  ﬂeas  at one  to  three,  four,
eight  and  12  h  after treatment  and  each  subsequent  infestation.  In the  egg  production  study,  sarolaner-
and  placebo-treated  dogs  were  similarly  challenged  with  ﬂeas  and  at 48  h  after  each  infestation  the  dogs
were housed  for 20  h  in cages  allowing  the  collection  and  counting  of  all ﬂea  eggs  produced  during  this
period.  Collected  eggs  were  incubated  to evaluate  hatch  and  development  to adults.  The  last  study  used
dogs  housed  in  a ﬂea-infested  simulated-home  environment.  Dogs  were  allocated  to treatment  with
either placebo  or sarolaner  tablets  providing  a  dose  of  2 mg/kg  once  a month  for  three  treatments.  Flea
infestations  were  assessed  by comb  counts  (ﬂeas  were  replaced  on the  dogs)  on  Days  14,  30,  44, 60,  74
and  90.
The speed  of  kill  studies  demonstrated  that  a single  2 mg/kg  oral  dose  of  sarolaner  started  killing
ﬂeas  within  three  to  four  hours  after treatment  or subsequent  re-infestations  for up to  a  month,  and
achieved  ≥98% control  of  ﬂeas  by eight  hours  after  treatment  or re-infestation  for 28 days.  In the  study  to
assess  effects  on ﬂea  reproduction,  a single  oral treatment  of  sarolaner  resulted  in  the  complete  cessation
of  egg-laying  for 35  days.  This  rapid  kill  of ﬂeas  and inhibition  of reproduction  were  conﬁrmed  in a
simulated-home  environment  where  the  existing  infestations  were  reduced  by >95%  within  two  weeks
of  the  ﬁrst  treatment  and  eliminated  from  the dogs  after  two  monthly  doses.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
The cat ﬂea, Ctenocephalides felis felis, is the major ectoparasite
f companion animals and is found worldwide (Rust and Dryden,
997). Adult ﬂeas are the only life stage commonly found on the
ost; eggs fall from the pelage and the larvae develop in the envi-
∗ Corresponding author.
E-mail address: robert.six@Zoetis.com (R.H. Six).
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304-4017/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ronment, feeding mainly on the dried blood in adult ﬂea feces
(Dryden, 1989; Krämer and Menke, 2001). Adult ﬂeas acquire a
host, mate and about 24 h after the ﬁrst blood meal, females start
laying eggs with each female ﬂea on the animal producing up
to 40–50 eggs/day (Rust and Dryden, 1997). Effective ﬂea con-
trol is dependent upon elimination of ﬂeas from the animal and
its environment. This can be achieved by combining an adulticide
with compounds such as the insect growth regulators, lufenuron,
pyriproxyfen and methoprene that disrupt the development of eggs
and larvae (Dryden and Broce, 2002; Chin et al., 2005). In fact,
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ffective control of infestations can be achieved with the use of
 compound such as lufenuron alone, though the animal is still at
isk of re-infestation from an external source. Alternatively, insec-
icides that have a rapid onset of activity can also disrupt the ﬂea
ife cycle by killing adult ﬂeas before they can lay eggs, thus reduc-
ng the environmental infestation level (Jacobs et al., 2001). For an
ctoparasiticide to prevent egg production, residual activity must
e sufﬁcient to kill newly acquired ﬂeas within 24 h, or produce suf-
cient toxicity to stop blood feeding and therefore egg production
Dryden et al., 2007).
Sarolaner is a new isoxazoline ectoparasiticide (McTier et al.,
016) with excellent efﬁcacy (>99%) against ﬂeas on dogs for
5 days following oral administration (Six et al., 2016). Here we
eport studies with an oral chewable formulation of sarolaner
SimparicaTM, Zoetis) evaluating speed of kill against existing
ea infestations and post-treatment challenges, effects on ﬂea
eproduction and efﬁcacy in a ﬂea-infested, simulated home envi-
onment.
. Materials and methods
The studies were conducted in accordance with the World Asso-
iation for the Advancement of Veterinary Parasitology (WAAVP)
uidelines for evaluating the efﬁcacy of parasiticides for the treat-
ent, prevention and control of ﬂea and tick infestation on dogs
nd cats (Marchiondo et al., 2013) and complied with Good Clini-
al Practices, (VICH guideline GL9) (EMEA, 2000). Study protocols
ere reviewed and approved by the local and/or Zoetis Institutional
nimal Care and Use Committee. All dogs used in these studies
ad not been treated with an ectoparasiticide for at least 60 days,
emonstrated good ﬂea retention prior to treatment and were in
ood health at enrollment. Dogs were housed individually in enclo-
ures that conformed to accepted animal welfare guidelines and
nsured no direct contact between dogs. Masking of all studies was
ssured through the separation of functions. All personnel conduct-
ng observations or animal care, or performing ﬂea infestations and
ounts were masked to treatment allocation.
Two studies were conducted to evaluate the speed of kill
f sarolaner against existing infestations and re-infestations of
at ﬂeas on dogs. The efﬁcacy of the minimum dose of 2 mg
arolaner/kg bodyweight against ﬂeas at 1, 2, 3, 4, 8, and 12 h after
 single oral dose and weekly ﬂea challenges up to 35 days was
etermined. Study 1 was conducted in Ireland and Study 2 in Cal-
fornia, USA. Study 3 was an evaluation of the effects of treatment
n ﬂea reproduction conducted in California, USA, and Study 4 was
 simulated ﬂea-infested environment study performed in Texas,
SA.
.1. Animals
Individually identiﬁed, purpose bred Beagles of both sexes were
sed in these studies. All dogs had not been treated with an ectopar-
siticide for at least 60 days, demonstrated good ﬂea retention prior
o treatment, and were in good health at enrolment. Dogs were indi-
idually housed in enclosures that conformed to accepted animal
elfare guidelines and ensured no direct contact between dogs.
ogs were fed an appropriate maintenance ration of a commercial
ry canine feed for the duration of the study. Water was  available ad
ibitum. Forty eight dogs from 10 to 64 months of age and weighing
rom 9.1 to 17.2 kg were used in the Study 1. Sixty four dogs from 10
o 142 months of age and weighing from 8.0 to 18.6 kg were used
n Study 2. Twenty dogs from 12 to 36 months of age and weighing
rom 8.4 to 12.4 kg were used in Study 3. Twenty four dogs from 6
o 8 months of age and weighing from 6.1 to 9.2 kg were used in
tudy 4.tology 222 (2016) 23–27
2.2. Experimental design and methods
2.2.1. General methods
Dogs were acclimated to the study conditions for at least 7 days
prior to treatment. The dogs were observed for general health at
least once daily throughout the studies. A physical exam was per-
formed on each dog by a veterinarian to determine health and
suitability prior to inclusion in the trial. For infestations, approx-
imately 100 cat ﬂeas (C. felis, ∼1:1 sex ratio) were applied directly
to the dogs and allowed to disperse into the hair coat. Flea counts
were performed by personnel trained in the standard procedures in
use at the test facility. Protective gloves and clothing were changed
between dogs and personnel conducting parasite or other obser-
vations were unaware of treatment assignments. The dogs were
thoroughly combed to count and remove ﬂeas. Fleas able to stand
upright and/or move in a coordinated manner were considered live.
Commercial ﬁne-toothed ﬂea combs were used. Dogs were sys-
tematically combed while standing using repeated strokes starting
from the head and proceeding caudally along the dorsum. The dog
was then placed in lateral recumbency and then on its back for
combing of the sides and ventral surfaces. Dogs were combed until
no ﬂeas were recovered during a 5 min  period. Each animal was
examined for a minimum of 10 min.
On each treatment day (Day 0 for all studies and also Days
30 and 60 for Study 4), the dogs were fasted overnight and then
offered their normal food ration ∼20 min  prior to dosing. In Study
1, dogs were administered a sarolaner tablet that was shaved and/or
sanded to the appropriate size to deliver the minimum dose of
2.0 mg  sarolaner/kg. Control dogs were dosed with a single placebo
tablet. In Studies 2, 3 and 4, dogs treated with sarolaner were
administered a single or combination of tablets from strengths of
5, 10, 20 or 40 mg  to achieve a dose as near as possible to 2.0 mg
sarolaner/kg without under dosing. Control dogs were dosed with
similarly-sized placebo tablets. All treatments were administered
by pilling to ensure complete dosing. Each dog was observed for
several minutes to ensure the dose was swallowed and for any
adverse events associated with administration, and then period-
ically for up to 2 h for any signs of emesis. Dogs were observed
for general health and any reaction to treatment approximately
1, 3 and 6 h after each treatment, then at least once daily for the
remainder of the study.
Study 1: Five days prior to treatment, a pool of suitable animals
was infested with ﬂeas. These dogs were then combed to count and
remove ﬂeas 24 ± 3 h later and the 48 dogs with the highest live
ﬂea counts were selected for inclusion in the study. The dogs were
ranked by ﬂea count into six blocks of eight and then the animals of
each block were randomly assigned to one of four placebo-treated
groups or four sarolaner-treated groups; resulting eight groups of
six dogs each. All dogs were infested with ﬂeas on Days −2, 7, 14,
21, 28 and 35. One placebo- and one sarolaner-treated group were
assessed for infestations by combing to count and remove ﬂeas at
1 h after treatment and after the Day 7 and 14 infestations and, then
at 2 h after the subsequent ﬂea infestations. Dogs in the remain-
ing placebo- and sarolaner-treated groups were combed to count
and remove ﬂeas at 4, 8, or 12 h after treatment and subsequent
infestations.
Study 2: Six or eight days prior to treatment, pools of suitable
animals were infested with ﬂeas. These dogs were then combed
to count and remove ﬂeas 24 ± 2 h later and the 64 dogs with the
highest live ﬂea counts were selected for inclusion in the study. The
dogs were ranked by ﬂea count into eight blocks and then randomly
assigned to one of four placebo-treated groups or four sarolaner-
treated groups to give eight groups of eight dogs. All dogs were
infested with ﬂeas on Days −1, 7, 14, 21, 28 and 35. Dogs from one
of each of the placebo and sarolaner groups were combed to count
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Table  1
Geometric mean ﬂea counts for placebo and sarolaner-treated dogs and percent efﬁcacy relative to placebo at various times after treatment and weekly infestations for
Beagles  treated orally with sarolaner tablets at 2 mg/kg (Study 1).
Time of count
Count Day 1 or 2 ha 4 h 8 h 12 h
Placebo Sarolaner Placebo Sarolaner Placebo Sarolaner Placebo Sarolaner
0 89.5 91.4 (0.0) 81.3 11.6* (85.7) 78.1 0.3* (99.6) 85.0 0.0* (100)
7  90.7 89.2 (1.6) 87.4 0.2* (99.8) 92.5 0.1* (99.9) 88.0 0.0* (100)
14  72.2 68.0 (5.8) 84.2 0.3* (99.6) 86.9 0.0* (100) 74.4 0.0* (100)
21  78.8 72.2 (8.4) 86.2 3.6* (95.8) 84.7 0.0* (100) 85.6 0.0* (100)
28  44.3 30.9 (30.1) 55.0 2.7* (95.1) 50.9 0.6* (98.9) 56.0 0.0* (100)
35  86.5 79.8 (7.7) 89.4 81.7 (8.3) 91.3 9.3* (89.8) 87.0 0.0* (100)
* Geometric mean counts are signiﬁcantly lower than placebo; P ≤ 0.0001. Percent efﬁcacy is given in parentheses.
a 1 h on Days 0–14, 2 h on Day 21–35.
Table 2
Geometric mean ﬂea counts for placebo and sarolaner-treated dogs and percent efﬁcacy relative to placebo at various times after treatment and weekly infestations for
Beagles  treated orally with sarolaner tablets at 2 mg/kg (Study 2).
Time of count
Count Day 3 h 4 h 8 h 12 h
Placebo Sarolaner Placebo Sarolaner Placebo Sarolaner Placebo Sarolaner
0 63.7 27.8* (56.3) 67.1 6.4* (90.4) 69.9 0.0* (100) 60.7 0.0* (100)
7  76.4 6.9* (91.0) 81.0 12.6* (84.4) 90.9 0.0* (100) 87.9 0.0* (100)
14  66.8 52.6 (21.3) 72.2 14.1* (80.4) 73.5 0.2* (99.7) 81.9 0.1* (99.9)
21  77.6 25.5* (67.2) 82.1 36.6* (55.4) 83.3 0.3* (99.6) 83.3 0.0* (100)
3* (40 * *
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35  76.7 74.5 (2.9) 79.4 58.
* Geometric mean counts are signiﬁcantly different to placebo; P ≤ 0.0217. Perce
nd remove ﬂeas at 3, 4, 8 or 12 h after treatment and subsequent
nfestations.
Study 3: Seven days prior to treatment, a pool of suitable ani-
als was infested with ﬂeas. These dogs were then combed to count
nd remove ﬂeas 24 ± 2 h later and the 20 dogs with the high-
st live ﬂea counts were selected for inclusion in the study. The
ogs were ranked by ﬂea count and randomly assigned to either
lacebo control or treatment with sarolaner. There were 10 dogs in
ach treatment group. The dogs were again infested with ﬂeas on
ays −1, 5, 12, 19, 26 and 33. At 48 ± 2 h after each infestation, the
ogs were placed in individual crates designed for the collection of
ea eggs and held in these cages for approximately 20 h. Just prior
o removal from the cages, the hair coat of each dog was  vigor-
usly rubbed to dislodge any retained ﬂea eggs. The dog was  then
emoved from the cage and combed to remove ﬂeas. All ﬂea eggs
ere carefully collected and counted. Two samples of up to 100
rbitrarily selected eggs from each dog were transferred to rearing
ontainers with larval growth medium and placed in an incuba-
or. At ﬁve days after collection, one container from each dog was
nspected and viable larvae were counted. Thirty ﬁve days after egg
ollection the second rearing container was checked and adult ﬂeas
ere counted.
Study 4: On Day −49, a pool of suitable animals was  infested
ith ﬂeas. These dogs were then combed to count and remove ﬂeas
4 ± 2 h later and the 24 dogs with the highest live ﬂea counts were
elected for inclusion in the study. The dogs were ranked by ﬂea
ount and randomly assigned to pens. The dogs were subsequently
nfested with ﬂeas on Days −42, −35, 7, 37 and 67. On Days −20,
6, 0, 14, 30, 44, 60, 74 and 90 the dogs were combed to count and
emove ﬂeas. On all of these days except Days 0 and 90, all viable
eas (up to a maximum of 100) combed off each dog were replaced
n that dog after combing. Fleas were not replaced on the animals
n Day 0, so that the challenge evaluated was derived from the
nfested environment. Following the Day −6 ﬂea counts, the dogs
n each pen were ranked by ﬂea count and randomly allocated to.5) 84.3 1.7 (98.0) 86.2 0.8 (99.1)
6) 81.9 3.1* (96.2) 80.7 3.5* (95.7)
cacy is given in parentheses.
either placebo control or treatment with sarolaner oral tablet. There
were 12 dogs in each treatment group.
2.2.2. Parasites
Study 1. The ﬂea colony was initially established by the Univer-
sity of Cardiff, UK and has been maintained in Ireland since 1996.
EU origin, ﬁeld-collected ﬂeas were last introduced to the colony
about eight years prior to conduct of the study.
Studies 2 and 3. The ﬂea colony was  established in 1997 with
wild ﬂeas collected in Turlock, California, USA. Locally collected
ﬂeas from naturally infested animals have been periodically added
to the colony, with the last introduction of wild ﬂeas occurring two
months prior to the start of study 2 and ﬁve months before Study
3 was  initiated.
Study 4. The colony was initiated with ﬂeas originally obtained
from Kansas State University. Additional ﬁeld collected ﬂeas from
California are introduced twice a year. The most recent introduction
was approximately 5 months prior to the study.
2.3. Data analysis
Studies 1, 2 and 4. The individual dog was the experimental unit
and the primary endpoint was live ﬂea count. Flea and tick counts
were transformed by the loge(count + 1) transformation prior to
analysis in order to stabilize the variance and normalize the data.
Using the PROC MIXED procedure (SAS 9.2, Cary NC), transformed
counts were analyzed a mixed linear model for repeated measures.
The models included the ﬁxed effects of treatment, day of study or
time of count, and any interactions. Random effects included block,
room, block within room, any interactions and error. Treatment
means were compared with the relevant control at the two-sided
signiﬁcance level  = 0.05. Percent efﬁcacy, relative to the control
group and based on geometric means, was calculated as follows:
%Efﬁcacy = (Mean Control - Mean Treated)
Mean Control
× 100
2  Parasitology 222 (2016) 23–27
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Table 3
Geometric mean ﬂea counts and ranges for placebo and sarolaner-treated dogs and
percent efﬁcacy relative to placebo for Beagles held in a ﬂea-infested, simulated
home environment and treated orally with sarolaner tablets at 2 mg/kg on Days 0,
30  and 60 (Study 4).
Count Day Placebo Sarolaner
Mean Range Mean Range % Efﬁcacy
0 92.5 19–328 102.2 31–402 –
14  99.6 33–375 4.4* 0–35 95.6
30  54.6 7–470 0.8* 0–4 98.6
44  65.4 21–317 0.2* 0–2 99.6
60  40.9 5–354 0.0* 0–0 100
74  44.6 13–411 0.0* 0–0 1006 R.H. Six et al. / Veterinary
In Study 3, the individual dog was the experimental unit and the
rimary endpoint was ﬂea egg count. Secondary variables exam-
ned were egg hatch and adult ﬂea emergence. Egg counts were
ransformed and analyzed as for ﬂea counts (described above).
he proportions of eggs hatching and adult ﬂeas emerging were
ubjected to an arcsine square-root transformation and analyzed
sing a general mixed linear model at each time point. The model
ncluded the ﬁxed effect of treatment and random effects of block
nd error. Testing was at the two-sided signiﬁcance level  = 0.05.
ercent reductions were calculated from back-transformed means
sing the above efﬁcacy formula.
. Results
.1. Efﬁcacy
Study 1. Placebo-treated animals maintained ﬂea infestations
hroughout the study (Table 1). Flea counts for sarolaner-treated
ogs were not signiﬁcantly different from placebo (P > 0.05) at one
our after treatment, one hour after infestations on Days 7 and 14,
wo hours after infestations on Days 21, 28 and 35, and at four
ours after infestation on Day 35. Live ﬂea counts at all other time
oints for sarolaner-treated dogs were signiﬁcantly lower than the
espective placebo group (P ≤ 0.0001) on all post-treatment count
ays. Against the pre-existing ﬂea infestation, efﬁcacy was  85.7,
9.6 and 100% at four, eight and 12 h after treatment, respectively.
or subsequent infestations, residual efﬁcacy was >95% within four
ours and >98% within eight hours after infestation for four weeks
fter treatment. At ﬁve weeks after treatment, 89.8% efﬁcacy was
chieved by eight hours after infestation. For all post-treatment
hallenges, 100% efﬁcacy was attained by 12 h after infestation.
Study 2. Placebo-treated animals maintained good ﬂea infes-
ations throughout the study (Table 2). Flea counts for sarolaner-
reated dogs were not signiﬁcantly different from placebo (P > 0.05)
t three hours after infestations on Days 14, 28 and 35, or at four
ours after infestation on Day 35. Live ﬂea counts at all other time
oints for sarolaner-treated dogs were signiﬁcantly lower than the
espective placebo group (P ≤ 0.0217) on all post-treatment count
ays. Against the pre-existing ﬂea infestation, efﬁcacy was  56.3,
0.4, 100 and 100% at three, four, eight and 12 h after treatment,
espectively. For subsequent infestations up to ﬁve weeks after
reatment, residual efﬁcacy ranged from 2.9 to 91.0% at three hours,
6.6–84.4% at four hours and was >95% at eight and twelve hours
fter infestation.
Study 3. Placebo-treated animals maintained ﬂea infestations
ollowing each challenge with large numbers of ﬂea eggs recov-
red from almost all dogs. The arithmetic mean egg counts ranged
rom 166 to 353 eggs/dog (individual dog range = 0–933) for the
ve weeks of the study. Flea egg counts for all sarolaner-treated
ogs were signiﬁcantly lower than the placebo group (P ≤ 0.0002)
n all post-treatment count days. There were no eggs collected from
ny sarolaner-treated animal throughout the study. The respective
ercentages of live larvae and adults that emerged from eggs col-
ected from the placebo-treated dogs ranged from 30 to 60% and 40
o 60%. As there were no eggs to incubate, no live larvae or adults
ere obtained from any sarolaner-treated dog.
Study 4. Ongoing infestation of the dogs’ environments was
emonstrated by the Day 0 (pretreatment) counts and conﬁrmed
n subsequent counts for the placebo-treated animals (Table 3).
n Day 0, dogs had a geometric mean pretreatment ﬂea count
f ∼100 ﬂeas/dog with individual counts ranging up to 402 ﬂeas
er dog, following infestation with a total of 200 ﬂeas each from
ve to six weeks previously. As more ﬂeas were recovered from
he dogs than could have been expected to survive, this indicated
hat ﬂeas were successfully breeding in the simulated environment.90  15.5 0–358 0.0* 0–0 100
* Geometric mean counts are signiﬁcantly different to placebo; P < 0.0001.
This was conﬁrmed by counts of more than 300 ﬂeas for individ-
ual placebo-treated animals on all counts after the initial treatment
(Table 3) as all adult ﬂeas were removed from the dogs on Day  0,
and additional induced infestations of 100 ﬂeas each were only con-
ducted on Days 7, 37, and 67. Live ﬂea counts for sarolaner-treated
dogs were signiﬁcantly lower than the placebo-treated dogs at all
post-treatment counts (P ≤ 0.0001). Reduction in ﬂea infestations
in sarolaner-treated dogs relative to placebo-treated dogs was  95.6,
98.6, and 99.6% on Days 14, 30 and 44, respectively, and 100% on
all subsequent count days.
3.2. Dose acceptance
All animals were successfully dosed. In Study 4, a single dog
regurgitated a complete sarolaner tablet directly after dosing on
Day 0. The tablet was  recovered immediately and successfully re-
administered. A small number of dogs in both treatments were
noted to either gag or cough following the administration of water
after the tablet was  dosed.
3.3. Health observations
There were no adverse events observed in any of the studies that
were considered related to sarolaner treatment.
4. Discussion
Taken together, the results of these four studies demonstrate
the rapid onset of efﬁcacy of sarolaner against adult ﬂeas starting
within 3–4 h of treatment or re-infestation, and producing ≥98%
reductions within 8 h through 28 days after treatment. This rapid
and complete efﬁcacy for a full month after a single dosing resulted
in the complete cessation of ﬂea reproduction on treated dogs for
up to 35 days and was  conﬁrmed under simulated infested envi-
ronment conditions.
In the ﬁrst investigation of the speed of kill versus ﬂeas (Study 1),
by four hours after sarolaner had been administered at an oral dose
of 2.0 mg/kg, ﬂea counts were signiﬁcantly lower in treated dogs
(P ≤ 0.0001) and efﬁcacy was 85.7%. Similarly, ﬂea counts were sig-
niﬁcantly lower in treated dogs than in placebo by four hours after
infestation for post-treatment challenges up to four weeks after
treatment (P ≤ 0.0001) and efﬁcacy was >95% through this period.
At Day 35, a signiﬁcant reduction in live ﬂeas of 89.8% (P ≤ 0.0001)
was achieved by 8 h after infestation.
In Study 2, live ﬂea counts were signiﬁcantly lower in sarolaner-
treated dogs than placebo within three hours of treatment and
infestations on Days 7 and 21 (P ≤ 0.0001) but not on Days 14, 28
and 35. Conﬁrming the previous study, at four hours after treatment
and post-treatment infestations for up to four weeks, sarolaner-
treated dogs had signiﬁcantly fewer live ﬂeas than placebo dogs
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P ≤ 0.0217) with efﬁcacies ranging from 40.5 to 90.4%. By eight
ours after treatment and subsequent infestations efﬁcacy was
6.2–100%.
These two  studies conﬁrmed that a 2 mg/kg oral dose of
arolaner started killing ﬂeas within three to four hours after
reatment or subsequent re-infestations for up to a month, and
chieved ≥98% control of ﬂeas by eight hours after treatment or
e-infestation for 28 days following a single treatment. This rapid
nset of effectiveness and consistent rapid kill of ﬂeas through a
onth after a single treatment compares favorably with other top-
cal and oral ﬂea products (Everett et al., 2000; Schenker et al., 2003;
ranc and Bouhsira, 2009). As complete kill was  obtained within
2 h through 35 days, monthly treatment with sarolaner could be
xpected to have an impact on the ability of ﬂeas to reproduce since
emale ﬂeas require at least 24 h on the host prior to the initiation
f egg laying (Dryden and Broce, 2002).
The impact of the rapid speed of kill of sarolaner on ﬂea
eproduction was conﬁrmed in Study 3, where no ﬂea eggs were
ecovered from one day after treatment or following weekly re-
nfestations through 35 days after treatment with a single oral dose
f sarolaner.
For dogs held in a ﬂea-infested simulated-home environment,
onthly treatment with sarolaner resulted in a rapid reduction
n ﬂea burden on the dogs and complete eradication of the ﬂea
nfestation within two months of treatment initiation. This efﬁcacy
esulted from the rapid speed of kill and cessation of egg-laying
hroughout the month long treatment period. Adult ﬂeas newly
merging from the infested environment were killed before they
ould reproduce and contribute to re-infestation of the environ-
ent. The small number of ﬂeas detected on sarolaner-treated dogs
p to about six weeks after the initiation of treatment were likely
ewly emerged ﬂeas derived from eggs laid prior to the ﬁrst dos-
ng; this is consistent with the ﬂea lifecycle (egg to adult) which can
ake up to eight weeks to complete (Rust and Dryden, 1997). The
omplete lack of any live ﬂeas on sarolaner-treated dogs for the last
ix weeks of the study was likely due to the rapid and consistent
ill of adult ﬂeas before they were able to lay eggs.
. Conclusions
The studies reported here demonstrated that a single oral dose
f sarolaner at 2 mg/kg provided rapid onset of activity and knock-
own of existing infestations of ﬂeas on dogs and quick and
onsistent kill of new infestations for at least one month. Fleas
tarted dying within three to four hours after treatment or sub-
equent re-infestations for up to a month and ≥98% control of ﬂeas
as achieved by eight hours after treatment or re-infestation for
8 days. This rapid and consistent speed of kill was shown to com-
letely suppress ﬂea egg-laying for one month following a single
reatment. The simulated infested home-environment study con-tology 222 (2016) 23–27 27
ﬁrmed the ability of monthly treatment of the host with sarolaner
to provide excellent control of existing environmental infestations
of ﬂeas.
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